Skadden, Arps, Slate, Meagher & Flom has advised Japan’s Nippon Shokubai on its acquisition of Sirrus, a U.S.-based chemical company, which was represented by Cooley. The financial terms of the transaction were not disclosed.
Founded as Bioformix in 2009, Sirrus has built a portfolio of more than 25 global patents that address process technologies, methods of application, initiation, formulation and stabilisation, as well as composition of matter for certain polymers.
“Combined with Sirrus’ intellectual property position, track record of innovation, and access to a broad range of customers and applications, the transaction is a strong strategic fit for Nippon Shokubai,” said Masanori Ikeda, the Japanese chemical giant’s president, in a statement.
The Skadden team was led by partners Mitsuhiro Kamiya, Michael Mies and Resa Schlossberg.